Xencor receives $215M royalty payment, Q3 net loss $(0.40)/share; cash runway into 2027

Xencor Inc

2023-Q3 EPS reported -$1.77 revenue$123,649,000

Royalty transaction with OMERS yields $215M upfront for portions of Ultomiris and Monjuvi royalties; cash runway extended to 2027.
Q3 revenue $59.2M, net loss $24.3M ($0.40 EPS) vs net loss $32.8M ($0.55 EPS) in Q3 2022.
Discontinued XmAb104 (PD-1 x ICOS) after Phase 1 expansion missed efficacy criteria; narrowed vudalimab enrollment.
Converted Genentech IL-15 co-development to milestone/royalty; plans to file IND for CLDN6 x CD3 (XmAb541) by year-end.
CFO John Kuch to retire March 2024; search for replacement initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xencor Inc reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Xencor, Inc. announced its financial results for the third quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.